493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

MLA

Daniel W. Hommes, et al. “493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn’s Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study.” Gastroenterology, vol. 134, Apr. 2008, p. A-67. EBSCOhost, https://doi.org/10.1016/s0016-5085(08)60317-0.

APA

Daniel W. Hommes, Leszek Paradowski, Pieter C. F. Stokkers, Subrata Ghosh, Gert A. Van Assche, Brian G. Feagan, Ad A. van Bodegraven, Yann Dean, Geert R. D’Haens, Zbigniew Hebzda, Paul Rutgeerts, Christien J. van der Woude, Dirk J. de Jong, Bas Oldenburg, Gerard Dijkstra, & Mahdi Farhan. (2008). 493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn’s Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study. Gastroenterology, 134, A-67. https://doi.org/10.1016/s0016-5085(08)60317-0

Chicago

Daniel W. Hommes, Leszek Paradowski, Pieter C. F. Stokkers, Subrata Ghosh, Gert A. Van Assche, Brian G. Feagan, Ad A. van Bodegraven, et al. 2008. “493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn’s Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study.” Gastroenterology 134 (April): A-67. doi:10.1016/s0016-5085(08)60317-0.